On the evening of the 21st, the Chengdu Research Base of Giant Panda Breeding issued an “Explanation on the Situation of Giant Panda ‘Baoxin’.” The specific content is as follows: Recently, some netizens have continued to pay attention to the giant...
On the evening of the 21st, the Chengdu Research Base of Giant Panda Breeding issued an “Explanation on the Situation of Giant Panda ‘Baoxin’.” The specific content is as follows:
Recently, some netizens have continued to pay attention to the giant panda "Baoxin". The relevant situation is explained as follows.
On March 3, 2023, the giant panda "Baoxin" developed clinical manifestations such as lethargy, refusal to eat, and poor mental performance. The medical team of the Panda Base immediately took diagnostic and treatment measures and organized a joint consultation with multidisciplinary experts. Based on the results of blood physiological and biochemical tests and imaging examinations such as CT and B-ultrasound, the patient was initially diagnosed as acute severe pancreatitis. Although he received 24-hour intensive care and treatment for more than ten days, "Baoxin" unfortunately passed away on March 14, 2023 due to multiple organ failure.
Currently, we have entrusted professional medical institutions to conduct pathological and histological examinations and conduct a comprehensive assessment of "Baoxin"'s early life, diagnosis and treatment process. The superior authorities attach great importance to it and are organizing authoritative experts to guide and help carry out cause analysis. After the report is formed, it will be announced to the public in a timely manner.
We deeply regret and are reluctant to leave "Baoxin". We would like to thank caring people from all walks of life for their care for "Baoxin". We will uphold the scientific spirit and scientific attitude and do our best to protect giant pandas.
Chengdu Research Base of Giant Panda Breeding
